(CSL) Carlisle Companies - Ratings and Ratios
Roofing, Insulation, Waterproofing, Barriers, Coatings, Panels
Dividends
| Dividend Yield | 1.27% |
| Yield on Cost 5y | 2.88% |
| Yield CAGR 5y | 15.91% |
| Payout Consistency | 94.0% |
| Payout Ratio | 21.0% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 31.9% |
| Value at Risk 5%th | 46.8% |
| Relative Tail Risk | -10.87% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.65 |
| Alpha | -34.82 |
| CAGR/Max DD | 0.34 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.507 |
| Beta | 0.913 |
| Beta Downside | 0.345 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.72% |
| Mean DD | 12.08% |
| Median DD | 9.17% |
Description: CSL Carlisle Companies October 30, 2025
Carlisle Companies Incorporated (NYSE:CSL) manufactures and supplies building-envelope products across the United States, Europe, and other international markets. The firm operates through two divisions: Carlisle Construction Materials (CCM), which provides single-ply roofing membranes (EPDM, TPO, PVC), polyiso insulation, and engineered metal roofing panels; and Carlisle Weatherproofing Technologies (CWT), which offers waterproofing systems, air-vapor barriers, sealants, spray polyurethane foam, and specialty insulation for commercial, residential, and industrial applications. Its portfolio of brands includes Carlisle SynTec, Versico, WeatherBond, Hunter Panels, Resitrix, and Hertalan.
Key recent metrics: • FY2023 revenue reached $2.0 billion, up ~5% YoY, driven by strong demand for energy-efficient roofing amid tightening building-code standards. • The company posted an adjusted EBITDA margin of ~12%, reflecting cost-discipline in raw-material sourcing and a shift toward higher-margin liquid-applied waterproofing products. • Macro drivers such as rising U.S. housing starts (projected 1.3 % annual growth) and increased capital-expenditure on commercial retrofits for climate resilience are supportive of Carlisle’s top-line outlook.
For a deeper quantitative view of Carlisle’s valuation metrics, you may find the analysis on ValueRay worth reviewing.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (776.1m TTM) > 0 and > 6% of Revenue (6% = 300.9m TTM) |
| FCFTA 0.15 (>2.0%) and ΔFCFTA 0.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 34.26% (prev 36.80%; Δ -2.54pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 1.09b > Net Income 776.1m (YES >=105%, WARN >=100%) |
| Net Debt (1.77b) to EBITDA (1.24b) ratio: 1.43 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.25 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (42.9m) change vs 12m ago -7.74% (target <= -2.0% for YES) |
| Gross Margin 36.24% (prev 37.98%; Δ -1.74pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 77.54% (prev 77.31%; Δ 0.24pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 15.37 (EBITDA TTM 1.24b / Interest Expense TTM 68.1m) >= 6 (WARN >= 3) |
Altman Z'' 8.20
| (A) 0.27 = (Total Current Assets 2.48b - Total Current Liabilities 764.7m) / Total Assets 6.46b |
| (B) 1.12 = Retained Earnings (Balance) 7.25b / Total Assets 6.46b |
| warn (B) unusual magnitude: 1.12 — check mapping/units |
| (C) 0.16 = EBIT TTM 1.05b / Avg Total Assets 6.47b |
| (D) 1.62 = Book Value of Equity 7.25b / Total Liabilities 4.46b |
| Total Rating: 8.20 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 75.89
| 1. Piotroski 6.0pt |
| 2. FCF Yield 6.21% |
| 3. FCF Margin 19.11% |
| 4. Debt/Equity 1.45 |
| 5. Debt/Ebitda 1.43 |
| 6. ROIC - WACC (= 10.76)% |
| 7. RoE 35.51% |
| 8. Rev. Trend -30.53% |
| 9. EPS Trend 33.64% |
What is the price of CSL shares?
Over the past week, the price has changed by +2.27%, over one month by +3.55%, over three months by -9.15% and over the past year by -20.96%.
Is CSL a buy, sell or hold?
- Strong Buy: 3
- Buy: 1
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CSL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 369.5 | 11.6% |
| Analysts Target Price | 369.5 | 11.6% |
| ValueRay Target Price | 338.9 | 2.4% |
CSL Fundamental Data Overview December 11, 2025
P/E Trailing = 18.2162
P/E Forward = 14.9925
P/S = 2.7221
P/B = 6.7573
P/EG = 0.9988
Beta = 0.957
Revenue TTM = 5.02b USD
EBIT TTM = 1.05b USD
EBITDA TTM = 1.24b USD
Long Term Debt = 2.88b USD (from longTermDebt, last quarter)
Short Term Debt = 4.50m USD (from shortTermDebt, last quarter)
Debt = 2.88b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.77b USD (from netDebt column, last quarter)
Enterprise Value = 15.43b USD (13.65b + Debt 2.88b - CCE 1.10b)
Interest Coverage Ratio = 15.37 (Ebit TTM 1.05b / Interest Expense TTM 68.1m)
FCF Yield = 6.21% (FCF TTM 958.5m / Enterprise Value 15.43b)
FCF Margin = 19.11% (FCF TTM 958.5m / Revenue TTM 5.02b)
Net Margin = 15.48% (Net Income TTM 776.1m / Revenue TTM 5.02b)
Gross Margin = 36.24% ((Revenue TTM 5.02b - Cost of Revenue TTM 3.20b) / Revenue TTM)
Gross Margin QoQ = 36.02% (prev 37.33%)
Tobins Q-Ratio = 2.39 (Enterprise Value 15.43b / Total Assets 6.46b)
Interest Expense / Debt = 0.74% (Interest Expense 21.3m / Debt 2.88b)
Taxrate = 23.15% (64.3m / 277.8m)
NOPAT = 804.3m (EBIT 1.05b * (1 - 23.15%))
Current Ratio = 3.25 (Total Current Assets 2.48b / Total Current Liabilities 764.7m)
Debt / Equity = 1.45 (Debt 2.88b / totalStockholderEquity, last quarter 1.99b)
Debt / EBITDA = 1.43 (Net Debt 1.77b / EBITDA 1.24b)
Debt / FCF = 1.85 (Net Debt 1.77b / FCF TTM 958.5m)
Total Stockholder Equity = 2.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.02% (Net Income 776.1m / Total Assets 6.46b)
RoE = 35.51% (Net Income TTM 776.1m / Total Stockholder Equity 2.19b)
RoCE = 20.66% (EBIT 1.05b / Capital Employed (Equity 2.19b + L.T.Debt 2.88b))
RoIC = 18.60% (NOPAT 804.3m / Invested Capital 4.32b)
WACC = 7.85% (E(13.65b)/V(16.53b) * Re(9.38%) + D(2.88b)/V(16.53b) * Rd(0.74%) * (1-Tc(0.23)))
Discount Rate = 9.38% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -6.34%
[DCF Debug] Terminal Value 75.41% ; FCFE base≈954.9m ; Y1≈1.07b ; Y5≈1.43b
Fair Price DCF = 469.0 (DCF Value 19.60b / Shares Outstanding 41.8m; 5y FCF grow 14.21% → 3.0% )
EPS Correlation: 33.64 | EPS CAGR: 19.02% | SUE: -0.15 | # QB: 0
Revenue Correlation: -30.53 | Revenue CAGR: -0.57% | SUE: 0.60 | # QB: 0
EPS next Quarter (2026-03-31): EPS=3.55 | Chg30d=-0.292 | Revisions Net=-4 | Analysts=9
EPS next Year (2026-12-31): EPS=20.78 | Chg30d=-1.787 | Revisions Net=-6 | Growth EPS=+8.8% | Growth Revenue=+2.7%
Additional Sources for CSL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle